CRD 733
Alternative Names: CRD-733; PDE9 inhibitor - Cardurion PharmaceuticalsLatest Information Update: 28 Nov 2024
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Cardurion Pharmaceuticals
- Class Cardiovascular therapies; Diagnostic agents; Heart failure therapies
- Mechanism of Action Phosphodiesterase 9A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Heart failure
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Heart-failure(In volunteers) in USA (PO)
- 28 Oct 2021 CRD 733 is still in phase I trials for Heart failure (In volunteers) in USA
- 28 Oct 2021 No recent reports of development identified for phase-I development in Heart-failure(In volunteers) in USA (PO)